The earnings call highlighted strong financial growth and promising vaccine development results, but also addressed significant challenges such as the stop work order on a major trial and issues with stock listing compliance. Despite positive advancements in revenue and vaccine capabilities, the operational and financial uncertainties create a balanced sentiment.

Company Guidance

During the Vaxart Business Update and Second Quarter 2025 Financial Results Conference Call, several key metrics were discussed. The company reported revenue of $39.7 million for the second quarter of 2025, a significant increase from $6.4 million in the same period of 2024. Vaxart ended the quarter with $26.3 million in cash, cash equivalents, and investments, projecting a cash runway into the first quarter of 2026. The COVID-19 Phase IIb trial enrolled approximately 5,000 participants before a stop work order was issued, with data anticipated by 2026. In their norovirus program, Phase I results showed statistically significant increases in blocking antibodies, with plans to advance to a Phase IIb study contingent on additional funding or partnership. The company also highlighted a reduction in workforce to align with business needs and reduce operating costs, emphasizing their ongoing focus on strategic partnerships and funding opportunities.

Significant Increase in Revenue

Revenue for the second quarter of 2025 was $39.7 million, compared to $6.4 million for the second quarter of 2024, primarily from the BARDA contract awarded in June 2024.

Positive Phase I Norovirus Vaccine Results

The second-generation norovirus vaccine constructs increased norovirus blocking antibodies, with statistical significance reached in the high-dose cohort. This demonstrates potential first-in-class or best-in-class capabilities.

Avian Influenza Vaccine Success in Preclinical Trials

The avian influenza vaccine showed 100% protection against death in a ferret challenge model, highlighting the potential for further development and partnerships.

Vaxart (VXRT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VXRT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-0.07 / -	-0.06	―	―	―
Aug 13, 2025	2025 (Q2)	-0.09 / -0.07	-0.09	22.22% (+0.02)	―
May 13, 2025	2025 (Q1)	-0.10 / -0.07	-0.14	50.00% (+0.07)	―
Mar 20, 2025	2024 (Q4)	-0.10 / -0.04	-0.11	63.64% (+0.07)	―
Nov 13, 2024	2024 (Q3)	-0.10 / -0.06	-0.11	45.45% (+0.05)	―
Aug 08, 2024	2024 (Q2)	-0.15 / -0.09	-0.16	43.75% (+0.07)	―
May 13, 2024	2024 (Q1)	-0.14 / -0.14	-0.19	26.32% (+0.05)	―
Mar 14, 2024	2023 (Q4)	-0.13 / -0.11	-0.18	38.89% (+0.07)	―
Nov 02, 2023	2023 (Q3)	-0.18 / -0.11	-0.23	52.17% (+0.12)
Aug 03, 2023	2023 (Q2)	-0.18 / -0.16	-0.23	30.43% (+0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VXRT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.37	$0.36	-2.70%
May 13, 2025	$0.42	$0.40	-4.76%
Mar 20, 2025	$0.57	$0.52	-8.77%
Nov 13, 2024	$0.71	$0.63	-11.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vaxart Inc (VXRT) report earnings?

Vaxart Inc (VXRT) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Vaxart Inc (VXRT) earnings time?

Vaxart Inc (VXRT) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VXRT EPS forecast?

VXRT EPS forecast for the fiscal quarter 2025 (Q3) is -0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing